Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell

다국어 초록 (Multilingual Abstract)

Background: EY-6 is one of the newly synthesized indoledione derivatives to induce tumor cell-specific cell death. In this study, we investigated the mechanism of immunological death induced by EY-6 at mouse colon cancer cell as well as at the normal immune cell represented by dendritic cell.
Methods: C57BL/6 mouse syngeneic colon cancer cell MC38 was treated with EY-6, and analyzed by MTT for viability test, flow cytometry for confirming surface expressing molecules and ELISA for detection of cytokine secretion.
Normal myeloid-dendritic cell (DC) was ex vivo cultured from bone marrow hematopoietic stem cells of C57BL/6 mice with GM-CSF and IL-4 to analyze the DC uptake of dead tumor cells and to observe the effect of EY-6 on the normal DC. Results: EY-6 killed the MC38 tumor cells in a dose dependent manner (25, 50 and 100μM) with carleticulin induction.
And EY-6 induced the secretion of IFN-γ but not of TNF-α from the MC38 tumor cells. EY-6 did not kill the ex-vivo cultured DCs at the dose killing tumor cells and did slightly but not significantly induced the DC maturation. The OVA-specific cross-presentation ability of DC was not induced by chemical treatment (both MHC II and MHC I-restricted antigen presentation). Conclusion: Data indicate that the EY-6 induced tumor cell specific and immunological cell death by modulation of tumor cell phenotype and cytokine secretion favoring induction of specific immunity eliminating tumor cells.

참고문헌 (Reference)

1 Galon J, "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome" 313 : 1960-1964, 2006

2 Chan OT, "The immunological effects of taxanes" 49 : 181-185, 2000

3 Kim JS, "Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]-phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity" PERGAMON-ELSEVIER SCIENCE LTD 15 (15): 451-457, 2007

4 유충규, "Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt" PERGAMON-ELSEVIER SCIENCE LTD 16 : 6001-6005, 200612

5 Chung KH, "Synthesis and biological evaluation of 5-arylamino-1H-benzo[d]imidazole- 4,7-diones as inhibitor of endothelial cell proliferation" 14 : 5795-501, 2006

6 Esumi N, "Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression" 51 : 1185-1189, 1991

7 Panaretakis T, "Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death" 28 : 578-590, 2009

8 Obeid M, "Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic" 67 : 7941-7944, 2007

9 Seo JM, "JM91, a newly synthesized indoledione derivative, inhibits rat aortic vascular smooth muscle cells proliferation and cell cycle progression through inhibition of ERK1/2 and Akt activations" PERGAMON-ELSEVIER SCIENCE LTD 75 : 1331-1340, 2008

10 Zitvogel L, "Immunological aspects of cancer chemotherapy" 8 : 59-73, 2008

11 Apetoh L, "Immunogenicity of anthracyclines: moving towards more personalized medicine" 14 : 141-151, 2008

12 Zitvogel L, "Immunogenic tumor cell death for optimal anticancertherapy: the calreticulin exposure pathway" 16 : 3100-3104, 2010

13 Janelidze S, "Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas" 32 : 593-601, 2009

14 Suzuki E, "Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity" 11 : 6713-6721, 2005

15 Nowak AK, "Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy" 62 : 2353-2358, 2002

16 North RJ, "Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells" 155 : 1063-1074, 1982

17 Machiels JP, "Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice" 61 : 3689-3697, 2001

18 Spreafico F, "Cancer chemotherapeutics as immunomodulators" 8 : 361-374, 1985

19 Obeid M, "Calreticulin exposure dictates the immunogenicity of cancer cell death" 13 : 54-61, 2007